This means the products in question will allow to remain on the market in the United States just as the company’s Vuse Solo products in original flavour that had been granted Marketing Authorization in October 2021.
The Marketing Authorization pertains to Vuse Vibe and Vuse Ciro original flavours while menthol still remains under review and may remain on the marketing pending the FDA’s final decision. All applications for other flavours were denied.
The press release went on to state that Vuse Alto remains under review and will continue to be available for adult nicotine consumers. The Vuse Alto PMTA was submitted nearly a year after Vuse Solo, and five months after Vuse Vibe and Ciro, and those applications share foundational science.
“These authorisations represent the broadest portfolio of Market Authorizations provided to any company in the US for Premarket Tobacco Product Applications (PMTA). Continued focus on science and innovation has supported the robust submissions, which have enabled FDA to evaluate and authorise the marketing of these products. We are proud of the work undertaken by the team to achieve this significant regulatory milestone and are confident in the quality of our applications,” said Dr. David O’Reilly, Director of Scientific Research, BAT.